Orthostatic hypotension

Summary

Orthostatic hypotension (MONDO:0005469) is a disease with 5 cohort genes (5 GWAS associations across 9 studies) and 93 clinical trials. Top therapeutic interventions include midodrine, droxidopa, and pyridostigmine.

At a glance

• Cohort genes: 5
• GWAS associations: 5
• Clinical trials: 93

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	orthostatic hypotension
Mondo ID	MONDO:0005469
EFO	EFO:0005252
ICD-10-CM	I95.1
ICD-11	56009591
SNOMED CT	28651003
UMLS	C0020651
MedGen	43803
Is cancer (heuristic)	no

Also known as: orthostatic hypotension · orthostatic hypotension (disease)

Data availability: 5 GWAS associations (9 studies) · 1 HPO phenotype.

Disease family

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › arterial disorder › hypotensive disorder › orthostatic hypotension

Related subtypes (4): supine hypotensive syndrome, acute hypotension, postprandial hypotension, neurally mediated hypotension

Genetics & variants

GWAS landscape

5 GWAS associations across 9 studies. Top hits map to 4 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs6736587	5e-08	RNA5SP99 - RN7SL201P	C	1.38
rs6892553	2e-06	RMEL3	G	1.08
rs16887217	4e-06	STAR	C	1.16
rs7098785	5e-06	PIK3AP1	T	0.9
rs4959677	9e-06	GMDS-DT	C	0.83

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90478057	Verma A	2024	13,638	418,629	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478056	Verma A	2024	2,837	114,107	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480817	Verma A	2024	2,837	114,107	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90080081	Backman JD	2021	2,084	385,821	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084067	Backman JD	2021	2,084	385,821	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90436184	Zhou W	2018	1,347	387,905	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90478055	Verma A	2024	1,008	57,069	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST002209	Hong KW	2013	667	5,761	Genome-wide association study of orthostatic hypotension and supine-standing blood pressure changes in two korean populations.
GCST90044032	Jiang L	2021	574	455,774	A generalized linear mixed model association tool for biobank-scale data.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	5

MAF distribution

Bucket	Variants
common (>=0.05)	5
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	4
intergenic_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs6736587	2	81628601	A>C	0.16	intergenic_variant	RNA5SP99 - RN7SL201P	5e-08	Tier 4: intronic/intergenic
rs6892553	5	57514311	T>A,C	0.137	intron_variant	RMEL3	2e-06	Tier 4: intronic/intergenic
rs16887217	8	38146907	T>C,G	0.105	intron_variant	STAR	4e-06	Tier 4: intronic/intergenic
rs7098785	10	96658173	A>G	0.361	intron_variant	PIK3AP1	5e-06	Tier 4: intronic/intergenic
rs4959677	6	2500586	G>C,T	0.216	intron_variant	GMDS-DT	9e-06	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
STAR	Orphanet:325524	Classic congenital lipoid adrenal hyperplasia due to STAR deficency
STAR	Orphanet:325529	Non-classic congenital lipoid adrenal hyperplasia due to STAR deficency
STAR	Orphanet:361	Familial glucocorticoid deficiency

Cohort genes → proteins

5 cohort genes, 5 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	5

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
STAR	HGNC:11359	ENSG00000147465	P49675	Steroidogenic acute regulatory protein, mitochondrial	gwas
ACTBL2	HGNC:17780	ENSG00000169067	Q562R1	Beta-actin-like protein 2	gwas
CTNNA2	HGNC:2510	ENSG00000066032	P26232	Catenin alpha-2	gwas
MYLK4	HGNC:27972	ENSG00000145949	Q86YV6	Myosin light chain kinase family member 4	gwas
PIK3AP1	HGNC:30034	ENSG00000155629	Q6ZUJ8	Phosphoinositide 3-kinase adapter protein 1	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
STAR	Steroidogenic acute regulatory protein, mitochondrial	Plays a key role in steroid hormone synthesis by enhancing the metabolism of cholesterol into pregnenolone.
ACTBL2	Beta-actin-like protein 2	Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells.
CTNNA2	Catenin alpha-2	May function as a linker between cadherin adhesion receptors and the cytoskeleton to regulate cell-cell adhesion and differentiation in the nervous system.
PIK3AP1	Phosphoinositide 3-kinase adapter protein 1	Signaling adapter that contributes to B-cell development by linking B-cell receptor (BCR) signaling to the phosphoinositide 3-kinase (PI3K)-Akt signaling pathway.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 4 · Druggable fraction: 0.2

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	5.5×	0.269
Other/Unknown	4	1.4×	0.269

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
STAR	Other/Unknown	no		StAR-like, START_lipid-bd_dom, START-like_dom_sf
ACTBL2	Other/Unknown	no		Actin, Actin_CS, Actin/actin-like_CS
CTNNA2	Other/Unknown	no		Vinculin_CS, Alpha_catenin, Vinculin/catenin
MYLK4	Kinase	yes		Prot_kinase_dom, Ser/Thr_kinase_AS, Kinase-like_dom_sf
PIK3AP1	Other/Unknown	no		TIR_dom, DBB_domain, Toll_tir_struct_dom_sf

Expression context

Cohort genes with no expression data: 0.

4 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	5
unknown	0

Top tissues across cohort

Tissue	Cohort genes
left adrenal gland	1
right adrenal gland	1
right adrenal gland cortex	1
cortical plate	1
islet of Langerhans	1
olfactory segment of nasal mucosa	1
Brodmann (1909) area 46	1
frontal pole	1
superior frontal gyrus	1
biceps brachii	1
deltoid	1
skeletal muscle tissue of biceps brachii	1
epithelial cell of pancreas	1
monocyte	1
parotid gland	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
STAR	184	broad	marker	right adrenal gland, right adrenal gland cortex, left adrenal gland
ACTBL2	24	tissue_specific	marker	cortical plate, islet of Langerhans, olfactory segment of nasal mucosa
CTNNA2	200	broad	marker	frontal pole, Brodmann (1909) area 46, superior frontal gyrus
MYLK4	172	tissue_specific	yes	biceps brachii, deltoid, skeletal muscle tissue of biceps brachii
PIK3AP1	207	broad	marker	parotid gland, epithelial cell of pancreas, monocyte

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
ACTBL2	3,277
CTNNA2	2,385
MYLK4	1,646
PIK3AP1	1,301
STAR	1,246

Structural data

PDB: 4 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
STAR	P49675	4
PIK3AP1	Q6ZUJ8	2
CTNNA2	P26232	1
MYLK4	Q86YV6	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
ACTBL2	Q562R1	94.97

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 21. Enrichment computed across 5 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Pregnenolone biosynthesis	1	271.9×	0.030	STAR
Metabolism of steroid hormones	1	173.0×	0.030	STAR
Myogenesis	1	126.9×	0.030	CTNNA2
PI3K/AKT Signaling in Cancer	1	122.8×	0.030	PIK3AP1
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	1	119.0×	0.030	PIK3AP1
Signaling by the B Cell Receptor (BCR)	1	115.3×	0.030	PIK3AP1
Negative regulation of the PI3K/AKT network	1	92.8×	0.032	PIK3AP1
Metabolism of steroids	1	45.9×	0.055	STAR
Constitutive Signaling by Aberrant PI3K in Cancer	1	42.3×	0.055	PIK3AP1
Mitochondrial protein degradation	1	38.1×	0.055	STAR
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	1	32.3×	0.057	PIK3AP1
Intracellular signaling by second messengers	1	30.4×	0.057	PIK3AP1
PIP3 activates AKT signaling	1	22.3×	0.071	PIK3AP1
Diseases of signal transduction by growth factor receptors and second messengers	1	18.9×	0.078	PIK3AP1
Metabolism of lipids	1	10.5×	0.128	STAR
Adaptive Immune System	1	9.9×	0.128	PIK3AP1
Disease	1	4.4×	0.247	PIK3AP1
Immune System	1	4.3×	0.247	PIK3AP1
Metabolism of proteins	1	4.1×	0.247	STAR
Metabolism	1	3.9×	0.248	STAR
Signal Transduction	1	3.4×	0.267	PIK3AP1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
radial glia guided migration of Purkinje cell	1	1123.5×	0.006	CTNNA2
positive regulation of bile acid biosynthetic process	1	1123.5×	0.006	STAR
regulation of synapse structural plasticity	1	842.6×	0.006	CTNNA2
toll-like receptor 2 signaling pathway	1	674.1×	0.006	PIK3AP1
toll-like receptor 7 signaling pathway	1	674.1×	0.006	PIK3AP1
axonogenesis	2	64.2×	0.006	ACTBL2, CTNNA2
negative regulation of Arp2/3 complex-mediated actin nucleation	1	481.5×	0.008	CTNNA2
toll-like receptor 9 signaling pathway	1	374.5×	0.008	PIK3AP1
glucocorticoid biosynthetic process	1	306.4×	0.008	STAR
regulation of steroid biosynthetic process	1	306.4×	0.008	STAR
modification of postsynaptic actin cytoskeleton	1	280.9×	0.008	CTNNA2
intracellular cholesterol transport	1	259.3×	0.008	STAR
prepulse inhibition	1	224.7×	0.009	CTNNA2
brain morphogenesis	1	146.5×	0.013	CTNNA2
regulation of neuron migration	1	124.8×	0.013	CTNNA2
steroid biosynthetic process	1	120.4×	0.013	STAR
toll-like receptor 4 signaling pathway	1	105.3×	0.014	PIK3AP1
regulation of neuron projection development	1	86.4×	0.016	CTNNA2
dendrite morphogenesis	1	86.4×	0.016	CTNNA2
cell motility	1	80.2×	0.016	ACTBL2
cholesterol metabolic process	1	39.2×	0.031	STAR
regulation of inflammatory response	1	33.7×	0.035	PIK3AP1
cell-cell adhesion	1	20.3×	0.055	CTNNA2
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	1	15.7×	0.067	PIK3AP1
cell migration	1	12.3×	0.082	CTNNA2
signal transduction	1	3.2×	0.275	MYLK4

Therapeutics

Drugs indicated for this disease

1 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Droxidopa	Approved (phase 4)
Ampreloxetine	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Atomoxetine, Ivabradine, Midodrine, Propranolol, Pyridostigmine.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 4

Druggability breadth: 2 of 5 evidence-associated genes (40%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
MYLK4	FEDRATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
MYLK4	13	4
STAR	0	0
ACTBL2	0	0
CTNNA2	0	0
PIK3AP1	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
FEDRATINIB	4	MYLK4
NINTEDANIB	4	MYLK4
SUNITINIB	4	MYLK4
MIDOSTAURIN	4	MYLK4
ENZASTAURIN	3	MYLK4
DOVITINIB	3	MYLK4
LESTAURTINIB	3	MYLK4
SU-014813	2	MYLK4
R-406	2	MYLK4
PICTILISIB	2	MYLK4
TOZASERTIB	2	MYLK4
KW-2449	1	MYLK4
BMS-387032	1	MYLK4

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
MYLK4	113	Binding:113
STAR	1	Binding:1

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
MYLK4	113

Pharmacogenomics

Cohort genes with a PharmGKB record: 5; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

13 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
FEDRATINIB	4	MYLK4
NINTEDANIB	4	MYLK4
SUNITINIB	4	MYLK4
MIDOSTAURIN	4	MYLK4
ENZASTAURIN	3	MYLK4
DOVITINIB	3	MYLK4
LESTAURTINIB	3	MYLK4
SU-014813	2	MYLK4
R-406	2	MYLK4
PICTILISIB	2	MYLK4
TOZASERTIB	2	MYLK4
KW-2449	1	MYLK4
BMS-387032	1	MYLK4

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	MYLK4
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	4	STAR, ACTBL2, CTNNA2, PIK3AP1

Undrugged target profiles

4 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
STAR	1	—
ACTBL2	0	—
CTNNA2	0	—
PIK3AP1	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 93.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	65
PHASE2	10
PHASE1	7
PHASE4	4
PHASE2/PHASE3	3
PHASE3	3
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01518946	PHASE4	COMPLETED	Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
NCT02632318	PHASE4	COMPLETED	Dawn Simulation and Postural Hypotension
NCT04440085	PHASE4	UNKNOWN	RaGuS Trial by Postoperative Patients
NCT04510922	PHASE4	COMPLETED	Lundbeck TOMs Orthostatic Hypotension
NCT00581477	PHASE2/PHASE3	TERMINATED	Treatment of Orthostatic Hypotension
NCT01176240	PHASE3	COMPLETED	A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson’s Disease
NCT01612078	PHASE3	TERMINATED	Phase 3 Study to Evaluate the Efficacy and Safety of Droxidopa on Orthostatic Hypotension Treatment in Hemodialysis Patients
NCT01707953	PHASE3	COMPLETED	Efficacy of Midodrine for the Prevention of Orthostatic Hypotension During Early Mobilization After Fast-track Hip Arthroplasty
NCT02919917	PHASE2/PHASE3	COMPLETED	Treatment of Post-SCI Hypotension
NCT05487300	PHASE2/PHASE3	COMPLETED	Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson’s Disease
NCT01370512	PHASE2	ENROLLING_BY_INVITATION	Droxidopa / Pyridostigmine in Orthostatic Hypotension
NCT06188663	PHASE2	RECRUITING	SalT Supplementation in Older Adults With Orthostatic Intolerance Disorders
NCT00004268	PHASE2	COMPLETED	Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension
NCT00426842	PHASE2	COMPLETED	A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride
NCT00835224	PHASE2	COMPLETED	Safety and Efficacy of L-NAME and Midodrine to Increase MAP
NCT00977171	PHASE2	TERMINATED	Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome
NCT01874782	PHASE2	COMPLETED	Transcranial Electrical Stimulation for Management of Orthostatic Instability in Acute Cervical Spinal Cord Injury
NCT02705755	PHASE2	COMPLETED	TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
NCT03482297	PHASE1/PHASE2	COMPLETED	Automated Abdominal Binder for Orthostatic Hypotension
NCT03674541	PHASE2	COMPLETED	The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
NCT05647473	PHASE2	UNKNOWN	Efficacy, Safety and Response Predictors of Adjuvant Astragalus for Cognition in Orthostatic Hypotension
NCT02726711	PHASE1	ACTIVE_NOT_RECRUITING	Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic
NCT02897063	PHASE1	RECRUITING	Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
NCT00103597	PHASE1	COMPLETED	Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson’s Disease and Multiple System Atrophy
NCT00223691	PHASE1	COMPLETED	Treatment of Orthostatic Hypotension in Autonomic Failure
NCT00748059	PHASE1	COMPLETED	The Pathophysiology of Orthostatic Hypotension
NCT01521221	PHASE1	UNKNOWN	Assessment of Hand-grip in the Prevention of Postural Orthostatic Hypotension
NCT02429557	PHASE1	COMPLETED	Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
NCT00580996	Not specified	ACTIVE_NOT_RECRUITING	Water and the Gastropressor Response - Tachyphylaxis
NCT00581373	Not specified	ACTIVE_NOT_RECRUITING	Water and the Gastropressor Response - Diurnal Variability
NCT04029974	Not specified	ACTIVE_NOT_RECRUITING	Speed of Robotic Leg Movements and Orthostatic Hypotension in Subacute SCI
NCT04493372	Not specified	RECRUITING	Deciphering Preserved Autonomic Function After Spinal Cord Injury
NCT05295810	Not specified	RECRUITING	Hypercapnia in Orthostatic Hypotension
NCT05369520	Not specified	RECRUITING	Non-invasive Spinal Cord Stimulation for Recovery of Autonomic Function After Spinal Cord Injury
NCT05400174	Not specified	RECRUITING	Blood Pressure Effects on Cognition and Brain Blood Flow in PD
NCT05621460	Not specified	RECRUITING	The Effect of Water Carbonation on Orthostatic Tolerance
NCT05725499	Not specified	RECRUITING	The Effect of Transcutaneous Stimulation on Blood Pressure in Spinal Cord Injury (SCI)
NCT05731986	Not specified	RECRUITING	Spinal Cord Transcutaneous Stimulation Effect on Blood Pressure in Acute Spinal Cord Injury (SCI)
NCT05960448	Not specified	RECRUITING	Autonomic Effects of Spinal Cord Stimulation in Spinal Cord Injury
NCT06439498	Not specified	ACTIVE_NOT_RECRUITING	Frequency of Orthostatic Hypotension in Patients Who Underwent Colonoscopy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MIDODRINE	4	25
DROXIDOPA	4	7
PYRIDOSTIGMINE	4	5
CARBIDOPA ANHYDROUS	4	3
ERGOTAMINE	4	3
OXYMETAZOLINE	4	3
EDROPHONIUM	4	2
ACARBOSE	4	1
ATROPINE	4	1
CAFFEINE	4	1
DIPHENHYDRAMINE HYDROCHLORIDE	4	1
DOMPERIDONE	4	1
FLUDROCORTISONE ACETATE	4	1
INDOMETHACIN	4	1
ISOPROTERENOL	4	1
LEVODOPA	4	1
METHYLDOPA	4	1
METOCLOPRAMIDE	4	1
MODAFINIL	4	1
NITROPRUSSIDE	4	1
OCTREOTIDE	4	1
PHENYLEPHRINE	4	1
PSEUDOEPHEDRINE	4	1
RANITIDINE HYDROCHLORIDE	4	1
RIVASTIGMINE TARTRATE	4	1
TRANYLCYPROMINE	4	1
TRIMETHAPHAN	4	1
YOHIMBINE	3	2
AMPRELOXETINE	3	1
TYRAMINE	3	1